{"title":"Exploring the efficacy and future prospects of nutritional and dietary therapies in Crohn's disease.","authors":"Takayuki Yamamoto","doi":"10.1080/17474124.2026.2667874","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nutritional therapy has progressed from supportive care to a targeted strategy in inflammatory bowel disease (IBD), particularly Crohn's disease (CD). Exclusive enteral nutrition (EEN) is firmly established as a first-line induction therapy in pediatric CD, achieving remission rates comparable to corticosteroids while simultaneously supporting growth and promoting mucosal healing.</p><p><strong>Areas covered: </strong>This review outlines enteral and dietary interventions in CD. A PubMed (MEDLINE) search identified relevant studies on nutritional and dietary interventions in CD published up to 17 August 2025. In children, EEN is validated; in adults, its use is more selective, with evidence supporting benefit in mild-to-moderate disease, intolerance to pharmacologic agents, and perioperative optimization. Elemental or low-residue formulas are particularly relevant for patients with stricturing disease or malnutrition. Partial enteral nutrition and structured exclusion diets, such as the Crohn's Disease Exclusion Diet (CDED), offer feasible long-term approaches. Regional differences persist, as Japan has established reimbursement pathways facilitating enteral nutrition, whereas Western countries generally prioritize pharmacologic therapies.</p><p><strong>Expert opinion: </strong>Enteral nutrition remains a valuable therapeutic option in CD when applied to carefully selected patients. Although biologics and small molecules dominate current management, individualized patient selection, adherence support, and multidisciplinary education are critical to maximize its therapeutic impact.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-13"},"PeriodicalIF":2.5000,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2026.2667874","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Nutritional therapy has progressed from supportive care to a targeted strategy in inflammatory bowel disease (IBD), particularly Crohn's disease (CD). Exclusive enteral nutrition (EEN) is firmly established as a first-line induction therapy in pediatric CD, achieving remission rates comparable to corticosteroids while simultaneously supporting growth and promoting mucosal healing.
Areas covered: This review outlines enteral and dietary interventions in CD. A PubMed (MEDLINE) search identified relevant studies on nutritional and dietary interventions in CD published up to 17 August 2025. In children, EEN is validated; in adults, its use is more selective, with evidence supporting benefit in mild-to-moderate disease, intolerance to pharmacologic agents, and perioperative optimization. Elemental or low-residue formulas are particularly relevant for patients with stricturing disease or malnutrition. Partial enteral nutrition and structured exclusion diets, such as the Crohn's Disease Exclusion Diet (CDED), offer feasible long-term approaches. Regional differences persist, as Japan has established reimbursement pathways facilitating enteral nutrition, whereas Western countries generally prioritize pharmacologic therapies.
Expert opinion: Enteral nutrition remains a valuable therapeutic option in CD when applied to carefully selected patients. Although biologics and small molecules dominate current management, individualized patient selection, adherence support, and multidisciplinary education are critical to maximize its therapeutic impact.
期刊介绍:
The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.